Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.

  • Revenue in USD (TTM)31.08bn
  • Net income in USD732.21m
  • Incorporated1925
  • Employees47.46k
  • Location
    Takeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
  • Phone+81 332782111
  • Fax+81 332782000
  • Websitehttps://www.takeda.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Alnylam Pharmaceuticals, Inc.2.35bn-269.70m41.06bn2.23k--355.53--17.49-2.09-2.0918.270.88580.58424.129.701,052,959.00-6.71-20.07-8.96-25.5186.0184.18-11.49-55.192.98-0.46270.8988--22.9759.2136.82---24.55--
Takeda Pharmaceutical Co Ltd (ADR)31.08bn732.21m47.63bn47.46k64.750.9828.071.530.22670.22679.7714.950.31211.307.25654,987.600.73671.710.88152.0465.5167.662.365.990.52022.520.3943123.757.456.84-25.0819.539.82--
Regeneron Pharmaceuticals Inc14.09bn4.50bn61.30bn15.11k14.452.0912.274.3539.3039.30123.45271.600.39170.63472.61932,457.3012.5118.5213.8921.1386.6987.2231.9437.924.03--0.0843--8.2712.5511.6115.8415.46--
Zoetis Inc9.29bn2.52bn68.99bn13.80k27.8314.8522.867.435.575.5720.5410.440.65291.077.00672,898.6017.7715.2521.8318.3170.9870.1827.2226.321.0421.140.585628.938.338.146.0610.637.3221.37
Data as of Jul 14 2025. Currency figures normalised to Takeda Pharmaceutical Co Ltd's reporting currency: US Dollar USD

Institutional shareholders

1.34%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (Global Investors)as of 31 Mar 202513.20m0.42%
Parametric Portfolio Associates LLCas of 31 Mar 20255.29m0.17%
Strategic Advisers LLCas of 31 Mar 20253.57m0.11%
Brandes Investment Partners LPas of 31 Mar 20253.50m0.11%
Adage Capital Management LPas of 31 Mar 20253.43m0.11%
Renaissance Technologies LLCas of 31 Mar 20253.16m0.10%
Goldman Sachs Asset Management LPas of 31 Mar 20252.89m0.09%
First Trust Advisors LPas of 31 Mar 20252.76m0.09%
Aperio Group LLCas of 31 Mar 20252.63m0.08%
Van Eck Associates Corp.as of 31 Mar 20252.17m0.07%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.